|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.70 EUR | -2.34% |
|
+5.56% | +14.77% |
| 06-16 | Zai Lab Receives EU Orphan Drug Designation for Lung Cancer Drug | MT |
| 06-10 | Asian Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading | MT |
Company Valuation: Zai Lab Limited
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 6,059 | 2,946 | 2,688 | 2,853 | 1,962 | 2,148 | - | - |
| Change | - | -51.37% | -8.77% | 6.15% | -31.23% | 9.5% | - | - |
| Enterprise Value (EV) 1 | 4,650 | 1,938 | 1,897 | 2,095 | 1,397 | 1,705 | 1,761 | 1,934 |
| Change | - | -58.33% | -2.13% | 10.47% | -33.34% | 22.09% | 3.28% | 9.81% |
| P/E | -8.29x | -6.63x | -7.9x | -10.1x | -11x | -8.63x | -10.3x | -14.2x |
| PBR | 4.35x | - | 3.34x | 3.36x | 2.73x | 4.02x | 4.32x | 4.28x |
| PEG | - | 0.2x | 0.3x | 0.4x | 0.3x | -0.2x | 0.7x | 0.5x |
| Capitalization / Revenue | 42x | 13.7x | 10.1x | 7.15x | 4.26x | 4.79x | 3.61x | 2.84x |
| EV / Revenue | 32.2x | 9.01x | 7.11x | 5.25x | 3.04x | 3.8x | 2.96x | 2.56x |
| EV / EBITDA | -6.7x | -4.89x | -5.3x | -7.75x | -6.51x | -7.02x | -11x | -29x |
| EV / EBIT | -6.64x | -4.79x | -5.17x | -7.43x | -6.09x | -6.59x | -10.1x | -22.5x |
| EV / FCF | -8.19x | -4.94x | -9.23x | -9.5x | -8.5x | -9.7x | -15.2x | -27.5x |
| FCF Yield | -12.2% | -20.2% | -10.8% | -10.5% | -11.8% | -10.3% | -6.58% | -3.63% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -7.58 | -4.63 | -3.46 | -2.6 | -1.6 | -2.215 | -1.865 | -1.347 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 144.3 | 215 | 266.7 | 399 | 460.2 | 448.7 | 595.6 | 755.9 |
| EBITDA 1 | -693.6 | -396.1 | -357.5 | -270.3 | -214.4 | -243 | -159.9 | -66.57 |
| EBIT 1 | -700.1 | -404.4 | -366.6 | -282.1 | -229.4 | -258.7 | -173.7 | -85.83 |
| Net income 1 | -704.5 | -443.3 | -334.6 | -257.1 | -175.5 | -240.9 | -156.5 | -125.8 |
| Net Debt 1 | -1,409 | -1,008 | -791.3 | -757.9 | -565.3 | -443.1 | -387.2 | -214.4 |
| Reference price 2 | 62.85 | 30.70 | 27.33 | 26.19 | 17.64 | 19.12 | 19.12 | 19.12 |
| Nbr of stocks (in thousands) | 96,409 | 95,972 | 98,349 | 108,937 | 111,219 | 112,355 | - | - |
| Announcement Date | 3/1/22 | 3/1/23 | 2/27/24 | 2/27/25 | 2/26/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 16.17x | 3.5x | 9.45x | 0.63% | 63.56B | |
| 27.72x | 5.64x | 16.51x | 0.57% | 55.92B | |
| 34.62x | 11.72x | 22.19x | -.--% | 41.68B | |
| -43.96x | 3.12x | 9.21x | 3.49% | 39.12B | |
| 33.87x | 3.61x | 11.1x | -.--% | 30.97B | |
| -8.4x | 12.02x | -7.38x | -.--% | 28.77B | |
| 16.52x | 3.14x | 9.5x | -.--% | 22.74B | |
| 50.1x | 5.51x | 37.82x | -.--% | 17.64B | |
| 25.89x | 5.38x | 14.42x | -.--% | 16.66B | |
| Average | 16.95x | 5.96x | 13.65x | 0.52% | 35.23B | |
| Weighted average by Cap. | 15.14x | 5.88x | 12.82x | 0.66% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ZLAB Stock
- 1ZL Stock
- Valuation Zai Lab Limited
Select your edition
All financial news and data tailored to specific country editions
